Cell-of-origin chromatin organization shapes the mutational landscape of cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
An analysis of cell-type-specific epigenomic features reveals a relationship between epigenomic and mutational profiles; chromatin characteristics can explain a large proportion of mutational variance in cancer genomes and the mutational distribution can identify the probable cell type from which a given cancer originated from. Genomic studies have shown that different cancer types vary substantially in the local density and types of somatic mutations. This has been explained not only by differences in DNA sequence but also by other features including epigenetic organization. Shamil Sunyaev and colleague now compare mutation densities to detailed epigenetic profiles of different cell types and tissues. They demonstrate that epigenomic features of a given cell type or tissue in which a cancer arises are much stronger determinants of mutational profiles than other properties. Conversely, the findings make it possible to deduce information on the possible tissue-of-origin of a tumour based on its mutational landscape. Cancer is a disease potentiated by mutations in somatic cells. Cancer mutations are not distributed uniformly along the human genome. Instead, different human genomic regions vary by up to fivefold in the local density of cancer somatic mutations1, posing a fundamental problem for statistical methods used in cancer genomics. Epigenomic organization has been proposed as a major determinant of the cancer mutational landscape1,2,3,4,5. However, both somatic mutagenesis and epigenomic features are highly cell-type-specific6,7. We investigated the distribution of mutations in multiple independent samples of diverse cancer types and compared them to cell-type-specific epigenomic features. Here we show that chromatin accessibility and modification, together with replication timing, explain up to 86% of the variance in mutation rates along cancer genomes. The best predictors of local somatic mutation density are epigenomic features derived from the most likely cell type of origin of the corresponding malignancy. Moreover, we find that cell-of-origin chromatin features are much stronger determinants of cancer mutation profiles than chromatin features of matched cancer cell lines. Furthermore, we show that the cell type of origin of a cancer can be accurately determined based on the distribution of mutations along its genome. Thus, the DNA sequence of a cancer genome encompasses a wealth of information about the identity and epigenomic features of its cell of origin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutation rates vary in different parts of the genome, at different stages of the life cycle and in diseases such as cancer, where they depend on the cell of origin, environmental exposure and cancer type [60][61][62] .”
From Advances in epigenetics link genetics to the environment and disease (2019) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Integrative analysis of 111 reference human epigenomes
Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) · Nature · doi:10.1038/nature14248 · Cited by 6,368
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Self-citationPermutation importance: a corrected feature importance measure
Altmann, A., Toloşi, L., Sander, O., & Lengauer, T. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq134 · Cited by 2,843
The accessible chromatin landscape of the human genome
Thurman, R. E., Rynes, E., Humbert, R., Vierstra, J., Maurano, M. T., Haugen, E., Sheffield, N. C., Stergachis, A. B., Wang, H., Vernot, B., et al. (2012) · Nature · doi:10.1038/nature11232 · Cited by 2,679
Self-citation
Cited by
Integrative analysis of 111 reference human epigenomes
Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) · Nature · doi:10.1038/nature14248 · Cited by 6,368
Self-citationThe molecular hallmarks of epigenetic control
Allis, C. D., & Jenuwein, T. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.59 · Cited by 2,809
Universal Patterns of Selection in Cancer and Somatic Tissues
Martincorena, I., Raine, K. M., Gerstung, M., Dawson, K. J., Haase, K., Van Loo, P., Davies, H., Stratton, M. R., & Campbell, P. J. (2017) · Cell · doi:10.1016/j.cell.2017.09.042 · Cited by 1,523
“…a statistical model ( dNdScv ) that combines the local observed synonymous mutation rate with a regression model using covariates that predict the variable mutation rate across the genome (Lawrence et al., 2013; Polak et al., 2015; Schuster-Bockler and Lehner, 2012) (Supplementary Methods S1.”
InfluentialAdvances in epigenetics link genetics to the environment and disease
Cavalli, G., & Heard, E. (2019) · Nature · doi:10.1038/s41586-019-1411-0 · Cited by 1,509
Genome-wide cell-free DNA fragmentation in patients with cancer
Cristiano, S., Leal, A., Phallen, J., Fiksel, J., Adleff, V., Bruhm, D. C., Jensen, S. Ø., Medina, J. E., Hruban, C., White, J. R., et al. (2019) · Nature · doi:10.1038/s41586-019-1272-6 · Cited by 1,476
A compendium of mutational cancer driver genes
Martínez-Jiménez, F., Muiños, F., Sentís, I., Deu-Pons, J., Reyes-Salazar, I., Arnedo-Pac, C., Mularoni, L., Pich, O., Bonet, J., Kranas, H., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0290-x · Cited by 1,296
Integrative omics for health and disease
Karczewski, K. J., & Snyder, M. P. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2018.4 · Cited by 1,158
“Studies integrating reference data sets of regulatory information 46,47 with WGS data from The Cancer Genome Atlas (TCGA) revealed a number of regulatory regions that are enriched for mutations in patients with cancer 68–71 .”
MethodFujimoto, A., Furuta, M., Totoki, Y., Tsunoda, T., Kato, M., Shiraishi, Y., Tanaka, H., Taniguchi, H., Kawakami, Y., Ueno, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3547 · Cited by 689
Parental influence on human germline de novo mutations in 1,548 trios from Iceland
Jónsson, H., Sulem, P., Kehr, B., Kristmundsdottir, S., Zink, F., Hjartarson, E., Hardarson, M. T., Hjorleifsson, K. E., Eggertsson, H. P., Gudjonsson, S. A., et al. (2017) · Nature · doi:10.1038/nature24018 · Cited by 561
Heterochromatin: Guardian of the Genome
Janssen, A., Colmenares, S. U., & Karpen, G. H. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062653 · Cited by 500
Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia
Granja, J. M., Klemm, S., McGinnis, L. M., Kathiria, A. S., Mezger, A., Corces, M. R., Parks, B., Gars, E., Liedtke, M., Zheng, G. X. Y., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0332-7 · Cited by 498
Role of non-coding sequence variants in cancer
Khurana, E., Fu, Y., Chakravarty, D., Demichelis, F., Rubin, M. A., & Gerstein, M. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2015.17 · Cited by 468
Evolutionary Determinants of Cancer
Greaves, M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0439 · Cited by 395
“The emergence of mutational complexity, clonal trajectories, or architectures and clinical subtypes is therefore constrained by the cell type of origin (54) and by the early or initiating mutations that reset genotypic signaling networks and cellular phenotypes (10, 55).”
BackgroundMutation bias reflects natural selection in Arabidopsis thaliana
Monroe, J. G., Srikant, T., Carbonell-Bejerano, P., Becker, C., Lensink, M., Exposito-Alonso, M., Klein, M., Hildebrandt, J., Neumann, M., Kliebenstein, D., et al. (2022) · Nature · doi:10.1038/s41586-021-04269-6 · Cited by 396
Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair
Haradhvala, N. J., Polak, P., Stojanov, P., Covington, K. R., Shinbrot, E., Hess, J. M., Rheinbay, E., Kim, J., Maruvka, Y. E., Braunstein, L. Z., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.050 · Cited by 411
“…genetic backgrounds and mutagenic exposures and by a non-uniform epigenomic landscape with variation in DNA replication timing, chromatin structure , and gene expression levels across the genome (Lawrence et al., 2013; Pleasance et al., 2010a, 2010b; Polak et al., 2014, 2015; Waddell et al., 2015).”
Self-citationSingle-cell whole-genome analyses by Linear Amplification via Transposon Insertion (LIANTI)
Chen, C., Xing, D., Tan, L., Li, H., Zhou, G., Huang, L., & Xie, X. S. (2017) · Science · doi:10.1126/science.aak9787 · Cited by 391
A model for RAS mutation patterns in cancers: finding the sweet spot
Li, S., Balmain, A., & Counter, C. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0076-6 · Cited by 384
The role of enhancers in cancer
Sur, I., & Taipale, J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.62 · Cited by 389
Whole genome sequencing analysis for cancer genomics and precision medicine
Nakagawa, H., & Fujita, M. (2018) · Cancer Science · doi:10.1111/cas.13505 · Cited by 375
Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment
Aponte, P. M., & Caicedo, A. (2017) · Stem Cells International · doi:10.1155/2017/5619472 · Cited by 375
“Sunyaev and his team showed in 2015 [198] by comparing cell-type-epigenomic characteristics and mutations between diverse tumor cells that chromatin accessibility and replication timing are better predictors of their capacity to generate more mutations than the mutation signature itself.”
BackgroundGenomic characterization of biliary tract cancers identifies driver genes and predisposing mutations
Wardell, C. P., Fujita, M., Yamada, T., Simbolo, M., Fassan, M., Karlic, R., Polak, P., Kim, J., Hatanaka, Y., Maejima, K., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.009 · Cited by 373
Self-citationReconstructing A/B compartments as revealed by Hi-C using long-range correlations in epigenetic data
Fortin, J.-P., & Hansen, K. D. (2015) · Genome Biology · doi:10.1186/s13059-015-0741-y · Cited by 333
“This confirms previous observations about the relationship between mutation rates and open and closed chromatin [Makova and Hardison, 2015], including cancer [Schuster-B¨ockler and Lehner, 2012, Polak et al., 2015].”
BackgroundMethodMularoni, L., Sabarinathan, R., Deu-Pons, J., Gonzalez-Perez, A., & López-Bigas, N. (2016) · Genome Biology · doi:10.1186/s13059-016-0994-0 · Cited by 336
“Nevertheless, the correct estimation of the background mutation rate of protein-coding genes requires accounting for many known—and probably also yet unknown—covariates, some of which can currently only be approximated [10].”
BackgroundTissue-specific tumorigenesis: context matters
Schneider, G., Schmidt-Supprian, M., Rad, R., & Saur, D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.5 · Cited by 311
Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder
Lim, E. T., Uddin, M., De Rubeis, S., Chan, Y., Kamumbu, A. S., Zhang, X., D'Gama, A. M., Kim, S. N., Hill, R. S., Goldberg, A. P., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4598 · Cited by 299
Nucleotide excision repair is impaired by binding of transcription factors to DNA
Sabarinathan, R., Mularoni, L., Deu-Pons, J., Gonzalez-Perez, A., & López-Bigas, N. (2016) · Nature · doi:10.1038/nature17661 · Cited by 300
Letouzé, E., Shinde, J., Renault, V., Couchy, G., Blanc, J.-F., Tubacher, E., Bayard, Q., Bacq, D., Meyer, V., Semhoun, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01358-x · Cited by 294
Different mutational rates and mechanisms in human cells at pregastrulation and neurogenesis
Bae, T., Tomasini, L., Mariani, J., Zhou, B., Roychowdhury, T., Franjic, D., Pletikos, M., Pattni, R., Chen, B.-J., Venturini, E., et al. (2018) · Science · doi:10.1126/science.aan8690 · Cited by 271
The topography of mutational processes in breast cancer genomes
Morganella, S., Alexandrov, L. B., Glodzik, D., Zou, X., Davies, H., Staaf, J., Sieuwerts, A. M., Brinkman, A. B., Martin, S., Ramakrishna, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms11383 · Cited by 257
Topoisomerase II beta interacts with cohesin and CTCF at topological domain borders
Uusküla-Reimand, L., Hou, H., Samavarchi-Tehrani, P., Rudan, M. V., Liang, M., Medina-Rivera, A., Mohammed, H., Schmidt, D., Schwalie, P., Young, E. J., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1043-8 · Cited by 255
The effects of chromatin organization on variation in mutation rates in the genome
Makova, K. D., & Hardison, R. C. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3890 · Cited by 253
An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping
Kawasaki, K., Toshimitsu, K., Matano, M., Fujita, M., Fujii, M., Togasaki, K., Ebisudani, T., Shimokawa, M., Takano, A., Takahashi, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.023 · Cited by 238
Rodak, O., Peris-Díaz, M. D., Olbromski, M., Podhorska-Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 233
“The epigenetic modification profiles occurring in neoplastic cells are strongly correlated with their histological lineage, creating chromatin mutation patterns characteristic of specific NSCLC subtypes [61].”
BackgroundNovel technologies and emerging biomarkers for personalized cancer immunotherapy
Yuan, J., Hegde, P. S., Clynes, R., Foukas, P. G., Harari, A., Kleen, T. O., Kvistborg, P., Maccalli, C., Maecker, H. T., Page, D. B., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0107-3 · Cited by 229
Recurrent somatic mutations in regulatory regions of human cancer genomes
Melton, C., Reuter, J. A., Spacek, D. V., & Snyder, M. (2015) · Nature Genetics · doi:10.1038/ng.3332 · Cited by 236
Ramazi, S., Allahverdi, A., & Zahiri, J. (2020) · Journal of Biosciences · doi:10.1007/s12038-020-00099-2 · Cited by 217
“…cells are created in effect of genetic alterations and the genomic instability in several classes of genes, such as oncogenes, tumor suppressor genes, apoptotic genes, and DNA repair genes (Audia and Campbell 2016; LeRoy et al. 2013; Lohrum et al. 2007; Polak et al. 2015; Rotili and Mai 2011).”
BackgroundJiao, W., Atwal, G., Polak, P., Karlic, R., Cuppen, E., PCAWG Tumor Subtypes and Clinical Translation Working Group, Al-Shahrour, F., Atwal, G., Bailey, P. J., Biankin, A. V., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13825-8 · Cited by 217
“Recent work has pointed to a strong correlation between the regional somatic mutation rate and chromatin accessibility as measured by DNase I sensitivity and histone mark 12 , and has suggested that the cell of origin can be inferred from regional mutation counts 13 .”
BackgroundSelf-citationHigh-throughput phenotyping of lung cancer somatic mutations
Berger, A. H., Brooks, A. N., Wu, X., Shrestha, Y., Chouinard, C., Piccioni, F., Bagul, M., Kamburov, A., Imielinski, M., Hogstrom, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.022 · Cited by 192
Chromatin regulatory mechanisms and therapeutic opportunities in cancer
Valencia, A. M., & Kadoch, C. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0258-1 · Cited by 208
A computationally fast variable importance test for random forests for high-dimensional data
Janitza, S., Celik, E., & Boulesteix, A.-L. (2018) · Advances in Data Analysis and Classification · doi:10.1007/s11634-016-0276-4 · Cited by 200
Transcription elongation factors represent in vivo cancer dependencies in glioblastoma
Miller, T. E., Liau, B. B., Wallace, L. C., Morton, A. R., Xie, Q., Dixit, D., Factor, D. C., Kim, L. J. Y., Morrow, J. J., Wu, Q., et al. (2017) · Nature · doi:10.1038/nature23000 · Cited by 200
Differential DNA repair underlies mutation hotspots at active promoters in cancer genomes
Perera, D., Poulos, R. C., Shah, A., Beck, D., Pimanda, J. E., & Wong, J. W. H. (2016) · Nature · doi:10.1038/nature17437 · Cited by 202
Precision Oncology: The Road Ahead
Senft, D., Leiserson, M. D. M., Ruppin, E., & Ronai, Z. A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.003 · Cited by 195
“Some methods also consider side information such as a gene’s replication timing and expression [94] [95], or per patient, and/or per gene mutation rates [96] (see references summarized in Table S2B).”
MethodRomanoski, C. E., Glass, C. K., Stunnenberg, H. G., Wilson, L., & Almouzni, G. (2015) · Nature · doi:10.1038/518314a · Cited by 192
Widespread Transcriptional Scanning in the Testis Modulates Gene Evolution Rates
Xia, B., Yan, Y., Baron, M., Wagner, F., Barkley, D., Chiodin, M., Kim, S. Y., Keefe, D. L., Alukal, J. P., Boeke, J. D., et al. (2020) · Cell · doi:10.1016/j.cell.2019.12.015 · Cited by 182
“Previous results have shown that the density of somatic mutations is negatively correlated with genomic features of open chromatin, likely due to greater DNA repair accessibility (Polak et al., 2015; Schuster-Böckler and Lehner, 2012).”
MutationalPatterns: the one stop shop for the analysis of mutational processes
Manders, F., Brandsma, A. M., de Kanter, J., Verheul, M., Oka, R., van Roosmalen, M. J., van der Roest, B., van Hoeck, A., Cuppen, E., & van Boxtel, R. (2022) · BMC Genomics · doi:10.1186/s12864-022-08357-3 · Cited by 170
Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals
Perez, S., Kaspi, A., Domovitz, T., Davidovich, A., Lavi-Itzkovitz, A., Meirson, T., Alison Holmes, J., Dai, C.-Y., Huang, C.-F., Chung, R. T., et al. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008181 · Cited by 172
“We have selected these specific modifications following previous report demonstrating that these epigenetic markers determine liver specific epigenetic profile [23].”
MethodBoot, A., Huang, M. N., Ng, A. W. T., Ho, S.-C., Lim, J. Q., Kawakami, Y., Chayama, K., Teh, B. T., Nakagawa, H., & Rozen, S. G. (2018) · Genome Research · doi:10.1101/gr.230219.117 · Cited by 181
“For some mutational processes, mutagenesis intensity varies by chromatin state (Polak et al. 2015; Seplyarskiy et al. 2015; Kaiser et al. 2016).”
BackgroundAn integrative ENCODE resource for cancer genomics
Zhang, J., Lee, D., Dhiman, V., Jiang, P., Xu, J., McGillivray, P., Yang, H., Liu, J., Meyerson, W., Clarke, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14743-w · Cited by 172
“After the release, the cancer genomics community embraced the ENCODE data, together with other functional genomic data, to study the mutational landscape and regulatory networks in cancer 2 – 8 .”
MethodMapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA
Bergstrom, E. N., Luebeck, J., Petljak, M., Khandekar, A., Barnes, M., Zhang, T., Steele, C. D., Pillay, N., Landi, M. T., Bafna, V., et al. (2022) · Nature · doi:10.1038/s41586-022-04398-6 · Cited by 169
Local Determinants of the Mutational Landscape of the Human Genome
Gonzalez-Perez, A., Sabarinathan, R., & Lopez-Bigas, N. (2019) · Cell · doi:10.1016/j.cell.2019.02.051 · Cited by 165
Circulating cell-free DNA for cancer early detection
Gao, Q., Zeng, Q., Wang, Z., Li, C., Xu, Y., Cui, P., Xin, Z., Lu, H., Wang, G., Cai, S., et al. (2022) · The Innovation · doi:10.1016/j.xinn.2022.100259 · Cited by 200
Insights into newly discovered marks and readers of epigenetic information
Andrews, F. H., Strahl, B. D., & Kutateladze, T. G. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2149 · Cited by 175
Reduced mutation rate in exons due to differential mismatch repair
Frigola, J., Sabarinathan, R., Mularoni, L., Muiños, F., Gonzalez-Perez, A., & López-Bigas, N. (2017) · Nature Genetics · doi:10.1038/ng.3991 · Cited by 155
Guo, Y. A., Chang, M. M., Huang, W., Ooi, W. F., Xing, M., Tan, P., & Skanderup, A. J. (2018) · Nature Communications · doi:10.1038/s41467-018-03828-2 · Cited by 148
Noncanonical secondary structures arising from non-B DNA motifs are determinants of mutagenesis
Georgakopoulos-Soares, I., Morganella, S., Jain, N., Hemberg, M., & Nik-Zainal, S. (2018) · Genome Research · doi:10.1101/gr.231688.117 · Cited by 146
Editing the Epigenome: Reshaping the Genomic Landscape
Holtzman, L., & Gersbach, C. A. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021632 · Cited by 143
“Therefore, the epigenome of a cell is believed to play a central role in regulating and maintaining gene expression, while its dysregulation has been tightly linked to numerous disorders in humans (81, 122, 144), such as type 2 diabetes (68, 134), Alzheimer’s disease (39, 115), Parkinson’s disease (52), fragile X synd…”
BackgroundImpact of risk factors on early cancer evolution
Weeden, C. E., Hill, W., Lim, E. L., Gronroos, E. C., & Swanton, C. (2023) · Cell · doi:10.1016/j.cell.2023.03.013 · Cited by 194
Widman, A. J., Shah, M. J., Frydendahl, A., Halmos, D., Khamnei, C. C., Øgaard, N., Rajagopalan, S., Arora, A., Deshpande, A. S., Hooper, W. F., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03040-4 · Cited by 169
SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia
Mar, B. G., Chu, S. H., Kahn, J. D., Krivtsov, A. V., Koche, R. P., Castellano, C. A., Kotlier, J. L., Zon, R. L., McConkey, M. E., Chabon, J. R., et al. (2017) · Blood · doi:10.1182/blood-2017-03-775569 · Cited by 147
Cancer driver mutations: predictions and reality
Ostroverkhova, D. S., Przytycka, T. M., & Panchenko, A. R. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.03.007 · Cited by 161
Epigenetic regulation of gene expression in cancer: techniques, resources and analysis
Kagohara, L. T., Stein-O’Brien, G., Kelley, D. Z., Flam, E. L., Wick, H. C., Danilova, L., Easwaran, H., Favorov, A. V., Qian, J. X., Gaykalova, D. A., et al. (2017) · Briefings in Functional Genomics · doi:10.1093/bfgp/elx018 · Cited by 149
“These mutations occur more frequently in regions of closed chromatin, which are inaccessible to DNA repair genes during replication [12].”
BackgroundPoetsch, A. R., Boulton, S. J., & Luscombe, N. M. (2018) · Genome Biology · doi:10.1186/s13059-018-1582-2 · Cited by 132
Mutational Signatures in Breast Cancer: The Problem at the DNA Level
Nik-Zainal, S., & Morganella, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2810 · Cited by 136
“Dynamic Cellular Processes and Mutational Signatures Thedistributionof somaticmutations is uneven through cancer genomes, has been extensively studied, and has been found to be largely influenced by replication time domains and histone epigenetic marks (50, 51).”
BackgroundNon-coding driver mutations in human cancer
Elliott, K., & Larsson, E. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00371-z · Cited by 166
Insertions and Deletions Target Lineage-Defining Genes in Human Cancers
Imielinski, M., Guo, G., & Meyerson, M. (2017) · Cell · doi:10.1016/j.cell.2016.12.025 · Cited by 129
“Our results build upon recently discovered links between epigenetic features of normal tissues and tumor-specific mutation patterns (Polak et al., 2015).”
The co-evolution of the genome and epigenome in colorectal cancer
Heide, T., Househam, J., Cresswell, G. D., Spiteri, I., Lynn, C., Mossner, M., Kimberley, C., Fernandez-Mateos, J., Chen, B., Zapata, L., et al. (2022) · Nature · doi:10.1038/s41586-022-05202-1 · Cited by 130
“…Mutect2 (version 4.1.4.1) using options ”–af-of-alleles-not-in resource 0.0000025 –germline-resource af-onlygnomad.hg38.vcf.gz” (Cibulskis et al., 2013; Poplin et al., 2018) Variants detected in any tumour sample (marked PASS, coverage AD 10 in both normal and tumour, at least 3 variant reads in…”
MethodInfluentialHu, C.-M., Tien, S.-C., Hsieh, P.-K., Jeng, Y.-M., Chang, M.-C., Chang, Y.-T., Chen, Y.-J., Chen, Y.-J., Lee, E. Y.-H. P., & Lee, W.-H. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.005 · Cited by 123
Danchin, É., Pocheville, A., Rey, O., Pujol, B., & Blanchet, S. (2018) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12453 · Cited by 168
“However, most information at this level results from correlations between chromatin landscape features and mutation rates, and the causality of this association remains to be fully explored (Ehrlich & Wang, 1981; Huttley, 2004; Schuster-Boeckler & Lehner, 2012; Makova & Hardison, 2015; Polak et al., 2015).”
BackgroundInfluentialThe somatic mutation landscape of the human body
García-Nieto, P. E., Morrison, A. J., & Fraser, H. B. (2019) · Genome Biology · doi:10.1186/s13059-019-1919-5 · Cited by 126
Mammary stem cells and progenitors: targeting the roots of breast cancer for prevention
Tharmapalan, P., Mahendralingam, M. J., Berman, H. K., & Khokha, R. (2019) · The EMBO Journal · doi:10.15252/embj.2018100852 · Cited by 137
Universal annotation of the human genome through integration of over a thousand epigenomic datasets
Vu, H., & Ernst, J. (2022) · Genome Biology · doi:10.1186/s13059-021-02572-z · Cited by 128
Oesophageal adenocarcinoma and gastric cancer: should we mind the gap?
Hayakawa, Y., Sethi, N. S., Sepulveda, A. R., Bass, A. J., & Wang, T. C. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.24 · Cited by 134
Kim, K., Punj, V., Kim, J., Lee, S., Ulmer, T. S., Lu, W., Rice, J. C., & An, W. (2016) · Genes & Development · doi:10.1101/gad.268714.115 · Cited by 127
“Recent landmark reports determined that differences in the “epigenomic signatures” of several H3NT PTMs are strongly correlated to the cell type-specific gene expression programs observed in >250 normal and diseased human tissues (Polak et al. 2015; Roadmap Epigenomics Consortium et al. 2015).”
BackgroundMapping and elucidating the function of modified bases in DNA
Raiber, E., Hardisty, R. E., van Delft, P., & Balasubramanian, S. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0069 · Cited by 138
“16 that occur, such that the mutation rate variation is linked to the epigenomic features of the cell of origin.(95,96,97)”
BackgroundA Simple Model-Based Approach to Inferring and Visualizing Cancer Mutation Signatures
Shiraishi, Y., Tremmel, G., Miyano, S., & Stephens, M. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005657 · Cited by 120
“A recent study found that epigenetic information in the cell types of origin of the corresponding tumors is the most predictive [41] for local mutation densities.”
BackgroundIn silico saturation mutagenesis of cancer genes
Muiños, F., Martínez-Jiménez, F., Pich, O., Gonzalez-Perez, A., & Lopez-Bigas, N. (2021) · Nature · doi:10.1038/s41586-021-03771-1 · Cited by 126
Diverse mutational landscapes in human lymphocytes
Machado, H. E., Mitchell, E., Øbro, N. F., Kübler, K., Davies, M., Leongamornlert, D., Cull, A., Maura, F., Sanders, M. A., Cagan, A. T. J., et al. (2022) · Nature · doi:10.1038/s41586-022-05072-7 · Cited by 116
Self-citationBayesian inference of negative and positive selection in human cancers
Weghorn, D., & Sunyaev, S. R. (2017) · Nature Genetics · doi:10.1038/ng.3987 · Cited by 136
Self-citationComputational analysis of cancer genome sequencing data
Cortés‐Ciriano, I., Gulhan, D., Lee, J. J.-K., Melloni, G. E. M., & Park, P. J. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00431-y · Cited by 134
“…statistical models that consider several variables that correlate with mutation frequency, including transcriptional activity, the timing of DNA replication 88 , epigenetic context (that is, open versus closed chromatin) 89,90 , DNA repair activity 91 and the sites of DNA-binding proteins 92–94 .”
BackgroundGuiblet, W. M., Cremona, M. A., Harris, R. S., Chen, D., Eckert, K. A., Chiaromonte, F., Huang, Y.-F., & Makova, K. D. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1269 · Cited by 115
“Other genomic features––such as recombination rate (8), replication timing (9), chromatin accessibility (10,11), histone modifications (12,13), and Lamina Associated Domains (14)––contribute to regional variation in mutation rates through the variable activity of different enzymatic processes along the genome.”
BackgroundMonitoring immune responses in the tumor microenvironment
Wargo, J. A., Reddy, S. M., Reuben, A., & Sharma, P. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.006 · Cited by 113
“Efforts are now also underway to characterize epigenetic alterations in tumor and immune cells that correlate with response to immunotherapy [40].”
BackgroundPan-cancer analysis of whole genomes
Campbell, P. J., Getz, G., Stuart, J. M., Korbel, J. O., & Stein, L. D. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/162784 · Cited by 114
Structural variations in cancer and the 3D genome
Dubois, F. P. B., Sidiropoulos, N., Weischenfeldt, J., & Beroukhim, R. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00488-9 · Cited by 129
LIST-S2: taxonomy based sorting of deleterious missense mutations across species
Malhis, N., Jacobson, M., Jones, S. J. M., & Gsponer, J. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa288 · Cited by 109
“Studies show that closed chromatin marks are found to be associated with regions of high cancer somatic mutation density compared to regions with high gene activity and open chromatin (29).”
BackgroundPortrait of a cancer: mutational signature analyses for cancer diagnostics
Van Hoeck, A., Tjoonk, N. H., van Boxtel, R., & Cuppen, E. (2019) · BMC Cancer · doi:10.1186/s12885-019-5677-2 · Cited by 107
Rouhani, F. J., Zou, X., Danecek, P., Badja, C., Amarante, T. D., Koh, G., Wu, Q., Memari, Y., Durbin, R., Martincorena, I., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01147-3 · Cited by 105
Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip
Goto, K., Suarez, A. A. R., Wrensch, F., Baumert, T. F., & Lupberger, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093057 · Cited by 113
An epigenetic gateway to brain tumor cell identity
Mack, S. C., Hubert, C. G., Miller, T. E., Taylor, M. D., & Rich, J. N. (2015) · Nature Neuroscience · doi:10.1038/nn.4190 · Cited by 109
Stem cells and origins of cancer in the upper gastrointestinal tract
Hayakawa, Y., Nakagawa, H., Rustgi, A. K., Que, J., & Wang, T. C. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.05.012 · Cited by 108
Bailey, S. D., Desai, K., Kron, K. J., Mazrooei, P., Sinnott-Armstrong, N., Treloar, A. E., Dowar, M., Thu, K. L., Cescon, D. W., Silvester, J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3650 · Cited by 104
“It is important that the lBMR and gBMR be calculated from DHSs and that these DHSs be cell type-specific, because somatic mutations have been shown to preferentially fall in heterochromatic noncoding regions in a cell type-specific manner 9,10 .”
Jühling, F., Hamdane, N., Crouchet, É., Shen, L., Saghire, H. E., Mukherji, A., Fujiwara, N., Oudot, M. A., Thumann, C., Saviano, A., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318918 · Cited by 108
“JQ1 treatment partially decreased c-Myc levels but the decrease did not reach significance (p=0.1580) (figure 4G, online supplementary figure S4).”
InfluentialZhu, H., Uusküla-Reimand, L., Isaev, K., Wadi, L., Alizada, A., Shuai, S., Huang, V., Aduluso-Nwaobasi, D., Paczkowska, M., Abd-Rabbo, D., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2019.12.027 · Cited by 101
Zhou, J., Azizan, E. A. B. A., Cabrera, C., Fernandes-Rosa, F. L., Boulkroun, S., Argentesi, G., Cottrell, E., Amar, L., Wu, X., O’Toole, S. M., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00906-y · Cited by 122
Cellular and molecular biology of small cell lung cancer: an overview.
Karachaliou, N., Pilotto, S., Lazzari, C., Bria, E., de Marinis, F., & Rosell, R. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2016.01.02 · Cited by 115
“Since mutation rate patterns can distinguish the cell-of-origin (25) this result suggests that SCLC and adenocarcinoma have a different progenitor, a finding that is in line with a recent study on transgenic SCLC mouse models (10).”
ResultChisholm, R. H., Lorenzi, T., & Clairambault, J. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.06.009 · Cited by 111
“voke subsequent mutations on the same genes? It has been proposed that mutations occur before the onset of epimutations [206], but it has also been reported that epigenetic silencing by methylation makes single nucleotide C to T mutations on the DNMT3A locus highly probable, entraining in turn more epigenetic alterati…”
BackgroundKazanov, M. D., Roberts, S. A., Polak, P. P., Stamatoyannopoulos, J. A., Klimczak, L. J., Gordenin, D. A., & Sunyaev, S. R. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.077 · Cited by 103
“The distributions of these features subsequently proved to be good predictors of regional differences in mutation density in cancers originated from the same tissues (Lawrence et al., 2013; Polak et al., 2015).”
Self-citationFinding driver mutations in cancer: Elucidating the role of background mutational processes
Brown, A.-L., Li, M., Goncearenco, A., & Panchenko, A. R. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006981 · Cited by 91
“The resulting mutation rate can vary throughout the genome by more than two orders of magnitude [10, 11] due to many factors operating on local and global scales [12-14].”
BackgroundEmergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations
Zhou, S., Treloar, A. E., & Lupien, M. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0745 · Cited by 100
Leukaemia 'firsts' in cancer research and treatment
Greaves, M. F. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.3 · Cited by 102
Metadata
- Authors
- Polak, P., Karlić, R., Koren, A., Thurman, R., Sandstrom, R., Lawrence, M. S., Reynolds, A., Rynes, E., Vlahoviček, K., Stamatoyannopoulos, J. A., & Sunyaev, S. R.
- Affiliations
- Broad Institute (US)
- University of Zagreb (HR)
- University of Washington (US)
- Corresponding author
- Stamatoyannopoulos, John A.
- Sunyaev, Shamil R.
- ORCID
- Venue
- Nature
- Published
- 2015-02-18
- Volume
- 518
- Issue
- 7539
- Pages
- 360-364
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4405175
- OpenAlex
- W2086239585
- Cited by
- 557
- References
- 29
- Citations by year
- 2026: 22 · 2025: 31 · 2024: 41 · 2023: 41 · 2022: 46 · 2021: 56 · 2020: 55 · 2019: 62 · 2018: 46 · 2017: 60 · 2016: 65 · 2015: 29
- FWCI
- 22.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (HL53750)
- National Heart, Lung, and Blood Institute (P01HL053750, P01 HL53750)
- National Institute of Mental Health (R01MH101244)
- National Human Genome Research Institute (U54HG007010)
- National Cancer Institute (U54CA143874)
- National Institute of Environmental Health Sciences (U01ES017156)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- cell of origin, chromatin accessibility, chromatin modification, DNA replication timing, somatic mutations, mutation density, tissue of origin prediction, cancer cell lines
- MeSH terms
- Chromatin, Humans, Melanocytes, Melanoma, Mutation, Neoplasms, Organ Specificity, Genome, Human, DNA Replication Timing, Epigenesis, Genetic, Cell Line, Tumor, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.